 Doxazosin therapy treatment diabetic hypertension incidence cardiovascular disease non-insulin-dependent diabetes NIDDM control hyperglycemia Hypertension dyslipidemia major determinants macrovascular disease patients high prevalence hypertension NIDDM antihypertensive drugs likely important determinants atherogenic lipid profile date completed major trial antihypertensive treatment outcome diabetic population drug choice treatment diabetic hypertension evidence studies nondiabetic groups short-term studies effects doxazosin antihypertensive therapy subjects NIDDM studies significant reduction blood pressure doxazosin treatment favorable effects serum lipid profile study adverse effects atenolol treatment glycemic control lipids lipoproteins Doxazosin therapy trend disturbances lipoprotein metabolism characteristic NIDDM metabolic effects effective lowering blood pressure doxazosin important determinants cardiovascular disease long term